Moderna Settles Patent Lawsuit with Genevant and Arbutus for up to $2.25bn.

jueves, 5 de marzo de 2026, 12:34 pm ET1 min de lectura
ABUS--
MRNA--

Moderna has agreed to pay up to $2.25bn to settle a patent infringement lawsuit with Genevant and Arbutus over the use of their lipid nanoparticle delivery technology in its mRNA-based Covid-19 vaccine. The deal grants Moderna a non-exclusive license to use the technology for infectious disease applications and ends all litigation between the companies.

Moderna Settles Patent Lawsuit with Genevant and Arbutus for up to $2.25bn.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios